Amanote Research
Register
Sign In
Prevention of Cardiovascular Outcomes in Diabetic Patients With Atrial Fibrillation: Direct Oral Anticoagulants or Warfarin?
Clinical pharmacology and therapy
doi 10.32756/0869-5490-2019-3-5-13
Full Text
Open PDF
Abstract
Available in
full text
Date
September 1, 2019
Authors
Unknown
Publisher
Pharmapress LLC
Related search
Characteristics and Outcomes in Patients With Atrial Fibrillation Receiving Direct Oral Anticoagulants in Off-Label Doses
BMC Cardiovascular Disorders
Cardiovascular Medicine
Cardiology
Cost-Effectiveness of New Oral Anticoagulants Compared With Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients With Atrial Fibrillation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Satisfaction With Oral Anticoagulants in Patients With Atrial Fibrillation
Patient Preference and Adherence
Pharmacology
Health Policy
Medicine
Toxicology
Social Sciences
Pharmaceutics
Effect and Risk of Novel Oral Anticoagulants Versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
Journal of Cardiology
Cardiovascular Medicine
Cardiology
Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation
JAMA network open
Medicine
Patients With Non-Valvular Atrial Fibrillation on Vitamin K Antagonists or Direct-Acting Oral Anticoagulants: Patients Profile and Long-Term Follow-Up Outcomes
Archivos de cardiolog�a de M�xico (English ed. Internet)
Safety and Efficacy of Direct Oral Anticoagulants for Atrial Fibrillation in Patients With Renal Impairment
Pharmacy
Underuse of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation in Italy
Internal and Emergency Medicine
Internal Medicine
Emergency Medicine
Clinical Outcomes and Cost-Effectiveness of Novel Oral Anticoagulants Incorporating Real-World Elderly Patients With Atrial Fibrillation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
